{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:17:45Z","timestamp":1787919465232,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["AstraZeneca"],"award-info":[{"award-number":["AstraZeneca"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many immunocompromised individuals continue to practice physical distancing behaviors to avoid severe COVID-19 outcomes. To measure the intensity of these physical distancing behaviors, we aimed to develop and validate a standardized metric across age groups: the Physical Distancing Scale for COVID-19 Avoidance (PDS-C19\u00a9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      PDS-C19 development involved content scoping, initial draft PDS-C19 design phase, and exploratory testing (via asynchronous online forums). Psychometric properties (structural validity, reliability, and construct validity) of the PDS-C19 were evaluated using a random sample of immunocompromised and non-immunocompromised participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091059) of the EAGLE Study, including adults and children aged 0.5\u201317 years from the US and UK. Adult caregivers of children aged\u2009\u2264\u200912 years completed a proxy version of the PDS-C19 on their behalf, in addition to providing self-reported responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Findings from the two asynchronous forums (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923 and\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) indicated that the items identified in the scoping phase were relevant and well-understood. As part of the structural validity analysis, item-response distributions, inter-item correlations, and exploratory factor analyses supported a nine-item unidimensional intensity scale. Confirmatory factor analyses reduced the PDS-C19 to seven items (two items were dropped due to high residual correlations or differential item functioning by age). Internal consistency was high (\u03c9\u2009=\u20090.97); convergent validity was good, with high correlations (\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      =0.74) with clinical outcome assessments of the ability to participate in activities and with worry. The PDS-C19 had good known-groups validity, with scores distinguishable by types of activities, level of worry, and number of close contacts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PDS-C19 had acceptable structural and construct validity and high internal consistency, demonstrating its value as a measure of physical distancing to avoid COVID-19 in immunocompromised and non-immunocompromised individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01150-w","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:25:11Z","timestamp":1785500711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of the Physical Distancing Scale for COVID-19 Avoidance (PDS-C19\u00a9) in immunocompromised and non-immunocompromised individuals and its validation in the EAGLE Study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-4173","authenticated-orcid":false,"given":"James C.","family":"Marcus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5711-8155","authenticated-orcid":false,"given":"Tiago","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-0390","authenticated-orcid":false,"given":"Paul","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9752-5758","authenticated-orcid":false,"given":"Renata T. C.","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7624-0091","authenticated-orcid":false,"given":"Sofie","family":"Arnetorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-8616","authenticated-orcid":false,"given":"Timothy A.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-5781","authenticated-orcid":false,"given":"Sudhir","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-3431","authenticated-orcid":false,"given":"Philip A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9590-0244","authenticated-orcid":false,"given":"Johan L. Hans","family":"Severens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-4357","authenticated-orcid":false,"given":"James W.","family":"Varni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-0611","authenticated-orcid":false,"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-0828","authenticated-orcid":false,"given":"Marieke","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-2149","authenticated-orcid":false,"suffix":"Jr.","given":"John E.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"7","key":"1150_CR1","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1377\/hlthaff.2020.00608","volume":"39","author":"C Courtemanche","year":"2020","unstructured":"Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A (2020) Strong social distancing measures in the United States reduced the COVID-19 growth rate. Health Affairs (Millwood) 39(7):1237\u20131246. https:\/\/doi.org\/10.1377\/hlthaff.2020.00608","journal-title":"Health Affairs (Millwood)"},{"key":"1150_CR2","unstructured":"Sutherland E, Headicar J, Delong P (2021) Coronavirus (COVID-19) Infection Survey technical article: waves and lags of COVID-19 in England, June 2021. Accessed 28 May 28 2024 https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/articles\/coronaviruscovid19infectionsurveytechnicalarticle\/wavesandlagsofcovid19inenglandjune2021"},{"key":"1150_CR3","unstructured":"GOV.UK (2020) Staying at home and away from others (social distancing). https:\/\/www.gov.uk\/government\/publications\/full-guidance-on-staying-at-home-and-away-from-others. Accessed 16 May 2024"},{"issue":"5","key":"1150_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/inthealth\/ihab037","volume":"13","author":"W Al-Salem","year":"2021","unstructured":"Al-Salem W, Moraga P, Ghazi H, Madad S, Hotez PJ (2021) The emergence and transmission of COVID-19 in European countries, 2019\u20132020: a comprehensive review of timelines, cases and containment. Int Health 13(5):383\u2013398. https:\/\/doi.org\/10.1093\/inthealth\/ihab037","journal-title":"Int Health"},{"key":"1150_CR5","unstructured":"Centers for Disease Control and Prevention (2020) Social distancing: keep a safe distance to slow the spread. https:\/\/stacks.cdc.gov\/view\/cdc\/90522. Accessed 20 May 2024"},{"issue":"1","key":"1150_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1186\/s12889-022-14368-2","volume":"22","author":"G Lasseter","year":"2022","unstructured":"Lasseter G, Compston P, Robin C, Lambert H, Hickman M, Denford S et al (2022) Exploring the impact of shielding advice on the wellbeing of individuals identified as clinically extremely vulnerable amid the COVID-19 pandemic: a mixed-methods evaluation. BMC Public Health 22(1):2145. https:\/\/doi.org\/10.1186\/s12889-022-14368-2","journal-title":"BMC Public Health"},{"issue":"1","key":"1150_CR7","doi-asserted-by":"publisher","first-page":"rkab003","DOI":"10.1093\/rap\/rkab003","volume":"5","author":"M Sloan","year":"2021","unstructured":"Sloan M, Gordon C, Lever E, Harwood R, Bosley MA, Pilling M et al (2021) COVID-19 and shielding: experiences of UK patients with lupus and related diseases. Rheumatol Adv Pract 5(1):rkab003. https:\/\/doi.org\/10.1093\/rap\/rkab003","journal-title":"Rheumatol Adv Pract"},{"issue":"9","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"e30460","DOI":"10.2196\/30460","volume":"7","author":"P Bachtiger","year":"2021","unstructured":"Bachtiger P, Adamson A, Maclean WA, Kelshiker MA, Quint JK, Peters NS (2021) Determinants of shielding behavior during the COVID-19 pandemic and associations with well-being among National Health Service patients: longitudinal observational study. JMIR Public Health Surveill 7(9):e30460. https:\/\/doi.org\/10.2196\/30460","journal-title":"JMIR Public Health Surveill"},{"issue":"4","key":"1150_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/AID.2020.0302","volume":"37","author":"JY Islam","year":"2021","unstructured":"Islam JY, Vidot DC, Havanur A, Camacho-Rivera M (2021) Preventive behaviors and mental health-related symptoms among immunocompromised adults during the COVID-19 pandemic: an analysis of the COVID impact survey. AIDS Res Hum Retroviruses 37(4):304\u2013313. https:\/\/doi.org\/10.1089\/AID.2020.0302","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"1150_CR10","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.7861\/fhj.2020-0205","volume":"8","author":"KA Westcott","year":"2021","unstructured":"Westcott KA, Wilkins F, Chancellor A, Anderson A, Doe S, Echevarria C et al (2021) The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis. Future Healthc J 8(1):e47\u2013e49. https:\/\/doi.org\/10.7861\/fhj.2020-0205","journal-title":"Future Healthc J"},{"issue":"3","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.23889\/ijpds.v7i3.1897","volume":"7","author":"J Butler","year":"2022","unstructured":"Butler J, Nath M, Blana D, Ball W, Beech N, Black C et al (2022) The clinically extremely vulnerable to COVID: identification and changes in healthcare while self-isolating (shielding) during the coronavirus pandemic. Int J Popul Data Sci 7(3):1897. https:\/\/doi.org\/10.23889\/ijpds.v7i3.1897","journal-title":"Int J Popul Data Sci"},{"issue":"3","key":"1150_CR12","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1093\/cid\/ciac501","volume":"76","author":"T Brosh-Nissimov","year":"2023","unstructured":"Brosh-Nissimov T, Hussein K, Wiener-Well Y, Orenbuch-Harroch E, Elbaz M, Lipman-Arens S et al (2023) Hospitalized patients with severe coronavirus disease 2019 during the omicron wave in Israel: benefits of a fourth vaccine dose. Clin Infect Dis 76(3):e234\u2013e239. https:\/\/doi.org\/10.1093\/cid\/ciac501","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1150_CR13","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2468-2667(23)00079-8","volume":"8","author":"L Nab","year":"2023","unstructured":"Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, Morley J et al (2023) Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health 8(5):e364\u2013e377. https:\/\/doi.org\/10.1016\/S2468-2667(23)00079-8","journal-title":"Lancet Public Health"},{"key":"1150_CR14","unstructured":"GOV.UK (2021) Moving to step 4 of the roadmap. https:\/\/www.gov.uk\/government\/publications\/covid-19-response-summer-2021-roadmap\/moving-to-step-4-of-the-roadmap. Accessed 16 May 2024"},{"key":"1150_CR15","unstructured":"Centers for Disease Control and Prevention (2023) CDC Museum COVID-19 timeline. https:\/\/www.cdc.gov\/museum\/timeline\/covid19.html. Accessed 19 Feb 2024"},{"key":"1150_CR16","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","volume":"35","author":"RA Evans","year":"2023","unstructured":"Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E et al (2023) Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur 35:100747. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"1150_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/03007995.2023.2233819","volume":"39","author":"A Ketkar","year":"2023","unstructured":"Ketkar A, Willey V, Pollack M, Glasser L, Dobie C, Wenziger C et al (2023) Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study. Curr Med Res Opin 39(8):1103\u20131118. https:\/\/doi.org\/10.1080\/03007995.2023.2233819","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1150_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3201\/eid2608.191493","volume":"26","author":"M Patel","year":"2020","unstructured":"Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z et al (2020) Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States. Emerg Infect Dis 26(8):1720\u20131730. https:\/\/doi.org\/10.3201\/eid2608.191493","journal-title":"Emerg Infect Dis"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","volume":"59","author":"S Shoham","year":"2023","unstructured":"Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P et al (2023) Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine 59:101965. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101965","journal-title":"EClinicalMedicine"},{"issue":"8","key":"1150_CR20","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","volume":"5","author":"FA Pearce","year":"2023","unstructured":"Pearce FA, Lim SH, Bythell M, Lanyon P, Hogg R, Taylor A et al (2023) Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. Lancet Rheumatol 5(8):e461\u2013e473. https:\/\/doi.org\/10.1016\/S2665-9913(23)00160-1","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"1150_CR21","doi-asserted-by":"publisher","first-page":"e220446","DOI":"10.1001\/jamaoncol.2022.0446","volume":"8","author":"M Obeid","year":"2022","unstructured":"Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvade V et al (2022) Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol 8(5):e220446. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0446","journal-title":"JAMA Oncol"},{"issue":"27","key":"1150_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","volume":"71","author":"JRC Singson","year":"2022","unstructured":"Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek J et al (2022) Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19\u2013COVID-NET, 10 states, March 2020-February 2022. MMWR Morbidity Mortal Wkly Rep 71(27):878\u2013884. https:\/\/doi.org\/10.15585\/mmwr.mm7127a3","journal-title":"MMWR Morbidity Mortal Wkly Rep"},{"key":"1150_CR23","unstructured":"Taylor CA, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (2024) COVID-19-associated hospitalizations among adults\u2013COVID-NET, 2023\u20132024. Presentation given to the Advisory Committee on Immunization Practices (ACIP), February 28. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-02-28-29\/02-COVID-Taylor-508.pdf. Accessed 4 Apr 2024"},{"key":"1150_CR24","unstructured":"GOV.UK (2023) COVID-19: guidance for people whose immune system means they are at higher risk. https:\/\/www.gov.uk\/government\/publications\/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk\/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk. Accessed 20 May 2024"},{"issue":"5","key":"1150_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.15585\/mmwr.mm7205e3","volume":"72","author":"P Patel","year":"2023","unstructured":"Patel P, Twentyman E, Koumans E, Rosenblum H, Griffin-Blake S, Jackson B et al (2023) Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating omicron sublineages - United States, January 2023. MMWR Morb Mortal Wkly Rep 72(5):128\u2013131. https:\/\/doi.org\/10.15585\/mmwr.mm7205e3","journal-title":"MMWR Morbidity Mortal Wkly Rep"},{"key":"1150_CR26","unstructured":"Bernardi L, Daniels J, Forgotten Lives UK, National Clinical Expert Group (2023) Forsaken but engaged: an inquiry into the psychological aspects of COVID-19, mental health, and political engagement of immunocompromised people. Accessed 19 Feb 2024 https:\/\/www.liverpool.ac.uk\/humanities-and-social-sciences\/research\/coronavirus-research\/forgotten-forsaken\/"},{"key":"1150_CR27","unstructured":"Centers for Disease Control and Prevention (2022) People with certain medical conditions. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. Accessed 9 Mar 2024"},{"issue":"10","key":"1150_CR28","doi-asserted-by":"publisher","first-page":"e33045","DOI":"10.1097\/MD.0000000000033045","volume":"102","author":"C Morgado-Toscano","year":"2023","unstructured":"Morgado-Toscano C, Gomez-Salgado J, Fagundo-Rivera J, Navarro-Abal Y, Rodriguez-Jimenez L, Climent-Rodriguez JA et al (2023) Anxiety and fear of COVID-19 in the UK general population: a cross-sectional study. Med (Baltim) 102(10):e33045. https:\/\/doi.org\/10.1097\/MD.0000000000033045","journal-title":"Med (Baltim)"},{"issue":"3","key":"1150_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr., Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220\u2013233. https:\/\/doi.org\/10.1097\/00005650-199603000-00003","journal-title":"Med Care"},{"key":"1150_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-016-0483-x","volume":"14","author":"JE Ware Jr","year":"2016","unstructured":"Ware JE Jr., Gandek B, Guyer R, Deng N (2016) Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS\u00ae). Health Qual Life Outcomes 14:84. https:\/\/doi.org\/10.1186\/s12955-016-0483-x","journal-title":"Health Qual Life Outcomes"},{"key":"1150_CR31","unstructured":"Ware JE Jr (2024) Quality of Life Disease Impact Scale\u20137 item scale (QDIS-7-item scale). https:\/\/eprovide.mapi-trust.org\/instruments\/quality-of-life-disease-impact-scale-7-item-scale. Accessed 9 Mar 2024"},{"key":"1150_CR32","unstructured":"Office for National Statistics (2018) Recommended national indicators of loneliness. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/wellbeing\/compendium\/nationalmeasurementofloneliness\/2018\/recommendednationalindicatorsofloneliness. Accessed 9 Mar 2024"},{"issue":"8","key":"1150_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS (2001) PedsQL\u2122 4.0: reliability and validity of the Pediatric Quality of Life Inventory\u2122 version 4.0 generic core scales in healthy and patient populations. Med Care 39(8):800\u2013812. https:\/\/doi.org\/10.1097\/00005650-200108000-00006","journal-title":"Med Care"},{"issue":"1","key":"1150_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11136-010-9730-5","volume":"20","author":"JW Varni","year":"2011","unstructured":"Varni JW, Limbers CA, Neighbors K, Schulz K, Lieu JE, Heffer RW et al (2011) The PedsQL\u2122 Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants. Qual Life Res 20(1):45\u201355. https:\/\/doi.org\/10.1007\/s11136-010-9730-5","journal-title":"Qual Life Res"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-7525-2-55","volume":"2","author":"JW Varni","year":"2004","unstructured":"Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P (2004) The PedsQL\u2122 Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes 2:55. https:\/\/doi.org\/10.1186\/1477-7525-2-55","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"1150_CR36","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"1150_CR37","unstructured":"EuroQoL Group (2024) EQ-5D. Accessed 9 Mar 2024 https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-y-about\/"},{"issue":"2","key":"1150_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271\u2013292. https:\/\/doi.org\/10.1016\/s0167-6296(01)00130-8","journal-title":"J Health Econ"},{"issue":"5","key":"1150_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"PharmacoEconomics"},{"issue":"6","key":"1150_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67(6):361\u2013370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"key":"1150_CR41","doi-asserted-by":"publisher","unstructured":"Prachthauser M, Cassisi JE, Le TA, Nicasio AV (2020) The Social Distance Scale (v1): a screening instrument to assess patient adherence to prevention strategies during pandemics. Int J Environ Res Public Health 17(21). https:\/\/doi.org\/10.3390\/ijerph17218158","DOI":"10.3390\/ijerph17218158"},{"key":"1150_CR42","doi-asserted-by":"publisher","first-page":"839656","DOI":"10.3389\/fpsyt.2022.839656","volume":"13","author":"S Chung","year":"2022","unstructured":"Chung S, Lee T, Hong Y, Ahmed O, Silva WAD, Gouin JP (2022) Viral anxiety mediates the influence of intolerance of uncertainty on adherence to physical distancing among healthcare workers in COVID-19 pandemic. Front Psychiatry 13:839656. https:\/\/doi.org\/10.3389\/fpsyt.2022.839656","journal-title":"Front Psychiatry"},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"1132169","DOI":"10.3389\/fpsyt.2023.1132169","volume":"14","author":"Y Hong","year":"2023","unstructured":"Hong Y, An H, Cho E, Ahmed O, Ahn MH, Yoo S et al (2023) Psychometric properties of the Korean version of questionnaires on adherence to physical distancing and health beliefs about COVID-19 in the general population. Front Psychiatry 14:1132169. https:\/\/doi.org\/10.3389\/fpsyt.2023.1132169","journal-title":"Front Psychiatry"},{"issue":"43","key":"1150_CR44","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.3346\/jkms.2023.38.e336","volume":"38","author":"SF Hammoudi","year":"2023","unstructured":"Hammoudi SF, Ahmed O, An H, Hong Y, Ahn MH, Chung S (2023) Adherence to physical distancing and health beliefs about COVID-19 among patients with cancer. J Korean Med Sci 38(43):e336. https:\/\/doi.org\/10.3346\/jkms.2023.38.e336","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1150_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17269\/s41997-020-00457-5","volume":"112","author":"JP Gouin","year":"2021","unstructured":"Gouin JP, MacNeil S, Switzer A, Carrese-Chacra E, Durif F, Knauper B (2021) Socio-demographic, social, cognitive, and emotional correlates of adherence to physical distancing during the COVID-19 pandemic: a cross-sectional study. Can J Public Health 112(1):17\u201328. https:\/\/doi.org\/10.17269\/s41997-020-00457-5","journal-title":"Can J Public Health"},{"key":"1150_CR46","doi-asserted-by":"publisher","first-page":"e52643","DOI":"10.2196\/52643","volume":"13","author":"P Williams","year":"2024","unstructured":"Williams P, Herring TA, Yokota RTC, Maia T, Venkatesan S, Marcus JC et al (2024) The association between physical distancing behaviors to avoid COVID-19 and health-related quality of life in immunocompromised and nonimmunocompromised individuals: patient-informed protocol for the observational, cross-sectional EAGLE Study. JMIR Res Protoc 13:e52643. https:\/\/doi.org\/10.2196\/52643","journal-title":"JMIR Res Protoc"},{"key":"1150_CR47","unstructured":"US Food and Drug Administration (FDA) (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 6 Mar 2024"},{"key":"1150_CR48","unstructured":"US Food and Drug Administration (FDA) (2022) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. Accessed 6 Mar 2024"},{"key":"1150_CR49","unstructured":"US Food and Drug Administration (FDA) (2022) Patient-focused drug development: methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 6 Mar 2024"},{"key":"1150_CR50","unstructured":"US Food and Drug Administration (FDA) (2019) Incorporating clinical outcome assessments into endpoints for regulatory decision-making https:\/\/www.fda.gov\/media\/132505\/download. Accessed 6 Mar 2024"},{"key":"1150_CR51","unstructured":"US Food and Drug Administration (FDA) (2017) Plan for issuance of patient-focused drug development guidance. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Plan-for-Issuance-of-Patient%E2%80%90Focused-Drug-Development-Guidance.pdf. Accessed 10 Mar 2024"},{"issue":"6","key":"1150_CR52","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1016\/j.jval.2023.03.1841","volume":"26","author":"T Maia","year":"2023","unstructured":"Maia T, Yokota R, Arnetorp S, Spiler J, Settergren G, Williams P (2023) PCR62 Post-lockdown behaviors and impacts of avoiding COVID-19 in individuals and caregivers of individuals at high-risk of severe COVID-19: a qualitative study. Value Health 26(6):S322. https:\/\/doi.org\/10.1016\/j.jval.2023.03.1841","journal-title":"Value Health"},{"issue":"6","key":"1150_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/0013164413495237","volume":"76","author":"EJ Wolf","year":"2013","unstructured":"Wolf EJ, Harrington KM, Clark SL, Miller MW (2013) Sample size requirements for structural equation models: an evaluation of power, bias, and solution propriety. Educ Psychol Meas 76(6):913\u2013934. https:\/\/doi.org\/10.1177\/0013164413495237","journal-title":"Educ Psychol Meas"},{"issue":"1","key":"1150_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/0013164415576187","volume":"76","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Shao C, Lathrop QN (2016) The mediated MIMIC model for understanding the underlying mechanism of DIF. Educ Psychol Meas 76(1):43\u201363. https:\/\/doi.org\/10.1177\/0013164415576187","journal-title":"Educ Psychol Meas"},{"issue":"2","key":"1150_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0146621619835496","volume":"44","author":"AK Montoya","year":"2020","unstructured":"Montoya AK, Jeon M (2020) MIMIC models for uniform and nonuniform DIF as moderated mediation models. Appl Psychol Meas 44(2):118\u2013136. https:\/\/doi.org\/10.1177\/0146621619835496","journal-title":"Appl Psychol Meas"},{"issue":"11","key":"1150_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S et al (2010) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol 63(11):1179\u20131194. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1150_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11336-008-9102-z","volume":"74","author":"W Revelle","year":"2009","unstructured":"Revelle W, Zinbarg RE (2009) Coefficients Alpha, Beta, Omega, and the glb: comments on Sijtsma. Psychometrika 74(1):145\u2013154. https:\/\/doi.org\/10.1007\/s11336-008-9102-z","journal-title":"Psychometrika"},{"key":"1150_CR58","volume-title":"Patient-reported outcomes: measurement, implementation and interpretation First ed","author":"JC Cappelleri","year":"2014","unstructured":"Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T (2014) Patient-reported outcomes: measurement, implementation and interpretation First ed. Chapman and Hall\/CRC, New York, NY"},{"key":"1150_CR59","unstructured":"Field A (2024) Discovering statistics using IBM SPSS statistics. Sage Publications Limited"},{"key":"1150_CR60","unstructured":"Navarro D (2015) Learning statistics with R: a tutorial for psychology students and other beginners. University of New South Wales"},{"issue":"4","key":"1150_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40121-025-01122-5","volume":"14","author":"J Pander","year":"2025","unstructured":"Pander J, Termorshuizen F, de Lange DW, Beekman-Hendriks W, Lanfermeijer J, Bakhshi-Raiez F et al (2025) The impact of the COVID-19 omicron variant on immunocompromised patients: ICU admissions and increased mortality. Infect Dis Ther 14(4):881\u2013888. https:\/\/doi.org\/10.1007\/s40121-025-01122-5","journal-title":"Infect Dis Therapy"},{"issue":"3","key":"1150_CR62","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.jinf.2025.106432","volume":"90","author":"JK Quint","year":"2025","unstructured":"Quint JK, Dube S, Carty L, Yokota R, Bell S, Turtle L et al (2025) Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study. J Infect 90(3):106432. https:\/\/doi.org\/10.1016\/j.jinf.2025.106432","journal-title":"J Infect"},{"key":"1150_CR63","doi-asserted-by":"publisher","unstructured":"Hughes K, Middleton DB, Nowalk MP, Balasubramani GK, Martin ET, Gaglani M et al (2021) Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults. Clin Infect Dis 73(11):e4353-e 4360. https:\/\/doi.org\/10.1093\/cid\/ciaa1927","DOI":"10.1093\/cid\/ciaa1927"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01150-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:50:53Z","timestamp":1787917853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01150-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was sponsored by AstraZeneca, conducted by IQVIA and performed in accordance with ethical principles consistent with the Declaration of Helsinki, Good Pharmacoepidemiology Practices (GPP) and the applicable legislation and\/or regulations on noninterventional studies and\/or observational studies. The study received institutional review board (IRB) approval in the United States [WCG IRB. Letter of approval of EAGLE Study Protocol v1.0 and related material. IRB tracking number: 20226100. November 15, 2022.], and IRB approval was not required in or obtained from the United Kingdom. In accordance with local regulations and the ethical principles that have their origin in the principles of the Declaration of Helsinki, all participants provided informed consent electronically before entering into the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JCM and MK are employees of IQVIA and may hold stock and\/or stock options in that company. TM was employed by IQVIA and may hold stock and\/or stock options in that company. PW was employed by AstraZeneca and may hold stock and\/or stock options in that company and is a current employee of IQVIA, which was under contract with AstraZeneca at the time of the study. RTCY is an employee of P95, which was under contract with AstraZeneca at the time of the study. SA and SV are employees of AstraZeneca and may hold stock and\/or stock options in that company. TAH and ST were employed by AstraZeneca and may hold stock and\/or stock options in that company. PAP was contracted by IQVIA and is on the Editorial Board for Quality of Life Research. JLS is employed by Severens HTA Consultancy, may hold stock, and\/or stock options in that company, and is under contract with IQVIA. JWV holds the copyright and the trademark for the PedsQL\u2122 and receives financial compensation from the Mapi Research Trust. JEWJ is an employee of John Ware Research Group and may hold stock and\/or stock options and is under contract with IQVIA. He also holds the copyright for the QDIS.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"157"}}